pharma · Malignant Pleural Mesothelioma · Bipolar I Depression
Sumitomo Pharma Co
Sumitomo Pharma (Suzhou) Co.,
Sumitomo Pharma (Suzhou) is a pharma organization headquartered in CN. Primary therapeutic focus areas include Malignant Pleural Mesothelioma, Bipolar I Depression, Carcinoma, Pancreatic Ductal, Bipolar Depression. NovaP
JP HQ
1897 Founded
193 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- JP
- Founded
- 1897
- Employees
- 193
- Programs
- 4
- Drugs
- 3
- Patents
- 0
BBI608
Phase 2 · small molecule · Malignant Pleural Mesothelioma
BBI608 for Malignant Pleural Mesothelioma is a Phase 2 program (small_molecule) at Sumitomo Pharma (Suzhou) Co., with 1 ClinicalTrials.gov record(s).
Internal code D8807005
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sumitomo Pharma (Suzhou) Co.,
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Malignant Pleural Mesothelioma
- Status
- completed
- Trials
- 1